Why, why, why de-lupus (does so badly in clinical trials)

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Professor David Isenberg has acted as a consultant for a number of companies including Merck Serono, GlaxoSmithKline, Eli Lilly and Celltech. The honoraria paid are transferred to a local arthritis charity. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Overview of biologic treatment in lupus.